Triple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003)

RecruitingOBSERVATIONAL
Enrollment

28

Participants

Timeline

Start Date

August 15, 2024

Primary Completion Date

July 1, 2027

Study Completion Date

July 1, 2028

Conditions
Hepatocellular Carcinoma Non-resectable
Interventions
COMBINATION_PRODUCT

TACE, Lenvatinib combination with Sintilimab sequential radiotherapy

TACE, Lenvatinib \[8mg(\<60kg)/12mg(\>60kg) orally daily\] combination with Sintilimab (200mg administered intravenous injection on Day 1 of each 21-day cycle) for 2 months. Sequential radiotherapy method and dosage are comprehensively evaluated by radiologists, hepatobiliary surgeons, and oncologists, and discussed by a multidisciplinary team

Trial Locations (4)

Unknown

NOT_YET_RECRUITING

First Affiliated Hospital of Fujian Medical University, Fuzhou

RECRUITING

Fujian Provincial Hospital, Fuzhou

NOT_YET_RECRUITING

Fujian provincial hospital, Fuzhou

NOT_YET_RECRUITING

Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou

All Listed Sponsors
lead

Fujian Provincial Hospital

OTHER